June 5, 2020 / 12:07 PM / 2 months ago

BRIEF-Arcturus Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Study Of ARCT-810

June 5 (Reuters) - Arcturus Therapeutics Holdings Inc :

* ARCTURUS THERAPEUTICS ANNOUNCES FIRST HEALTHY VOLUNTEER DOSED IN PHASE 1 STUDY OF ARCT-810 FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below